FINWIRES · TerminalLIVE
FINWIRES

研究快讯:App业绩超预期,但第二季度业绩指引可能不够令人满意

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:APP公布了强劲的2026年第一季度业绩,营收达18.42亿美元,同比增长59%,超出预期6700万美元,也超出市场普遍预期6000万美元。GAAP每股收益为3.56美元,超出预期0.10美元;调整后EBITDA为15.57亿美元,同比增长66%,利润率从2025年第一季度的81%提升至85%。该公司凭借其人工智能驱动的广告平台,继续展现出行业领先的盈利能力和运营杠杆,持续经营业务的净利润率达到65%。2026年第二季度营收预期为19.15亿美元至19.45亿美元(中值为19.3亿美元),高于市场普遍预期的18.98亿美元,但环比增速放缓至约5%。强劲的资本回报持续,第一季度回购股票10亿美元,使公司在2025年底的流通股数量从3.38亿股减少至3.36亿股。自由现金流达12.87亿美元,自由现金流利润率高达70%,而公司的“40法则”得分也远高于140。管理层预期公司将实现50%以上的增长,这反映了业务持续强劲的需求势头。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661